<DOC>
	<DOCNO>NCT02600897</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , pharmacokinetics induction treatment obinutuzumab , polatuzumab vedotin , lenalidomide participant relapse refractory FL DLBCL . Participants FL achieve complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) end induction therapy receive post-induction treatment obinutuzumab lenalidomide , participant DLBCL achieve CR PR end induction also eligible post-induction treatment .</brief_summary>
	<brief_title>A Study Obinutuzumab , Polatuzumab Vedotin , Lenalidomide Relapsed Refractory Follicular Lymphoma ( FL ) Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Age great equal ( &gt; /= ) 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Histologically document cluster differentiation ( CD ) 20positive Bcell lymphoma classify either follow : relapsed refractory FL treatment least one prior chemoimmunotherapy regimen include antiCD20 monoclonal antibody ( mAb ) appropriate treatment option exists , relapse refractory DLBCL treatment least one prior chemoimmunotherapy regimen autologous stemcell transplantation ( SCT ) indicate At least one bidimensionally measurable lesion Agreement remain abstinent use adequate contraception , among woman men childbearing potential Known CD20negative status relapse progression Central nervous system ( CNS ) disease Prior allogeneic SCT , autologous SCT within 100 day prior Day 1 Cycle 1 Current use systemic immunosuppressant ( ) , prior anticancer therapy include : lenalidomide , fludarabine , alemtuzumab within 12 month ; radioimmunoconjugate within 12 week ; mAb antibodydrug conjugate within 4 week ; radiotherapy/chemotherapy/hormone therapy/targeted smallmolecule therapy within 2 week prior Day 1 Cycle 1 Active infection Positive human immunodeficiency virus ( HIV ) hepatitis B C Receipt live virus vaccine within 28 day prior Day 1 Cycle 1 Poor hematologic , renal , hepatic function Pregnant lactating woman Life expectancy le ( &lt; ) 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>